CD19-CD22 Chimeric Antigen Receptor T (CAR-T) Cell for Treatment of B Cell Acute Lymphoblastic Leukemia (B-ALL)

a Feasibility and Safety Study of Bispecific CD19-CD22 CAR-T Cell in the Treatment of Relapsed or Refractory B-ALL

This is a single arm, open-label, single center study to determine the safety and efficacy of CD19-CD22 CAR-T cells in patients with CD19+CD22+ Leukemia.

Study Overview

• Status: Terminated
• Conditions: Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia
• Intervention / Treatment: Biological: CD19-CD22 CAR-T cells

Detailed Description

This is a single arm, open-label, single center study to determine the safety and efficacy of CD19-CD22 CAR-T cells in patients with relapsed or refractory B-ALL. The study will have the following sequential phases: Screening, Pre-Treatment (Cell Product Preparation & Lymphodepleting Chemotherapy), Treatment and Follow-up, and Survival Follow-up. The total duration of the study is 2 years from CD19-CD22 CAR-T cell infusion.

• Study Type: Interventional
• Enrollment (Actual): 2
• Phase: Early Phase 1

Contacts and Locations

Study Locations

• China
  • Tianjin, China, 300020
    • Institute of Hematology & Blood Diseases Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 3 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

1. Informed consent is signed by a subject or his lineal relation.
2. Age 3 and older.
3. Documentation of cluster of differentiation 19 (CD19) and or cluster of differentiation 19 (CD22) expression on leukemic blasts in the BM, peripheral blood within 3 months of screening.;

4. Relapsed or refractory B-cell ALL

   • Relapse within 12 months of first remission
   • Without remission after 2 cycles of induction chemotherapy regimen.
   • Without remission or relapse after salvage treatments.
   • Any BM relapse after autologous stem cell transplantation (ASCT).
5. Without remission or relapse after any prior CD19 targeted therapy;
6. Patients with Philadelphia chromosome positive (Ph+) ALL are eligible if they are intolerant to or have failed 2 lines of tyrosine kinase inhibitor therapy (TKI); no TKI salvage treatments if the patient has a BCR-ABL1 kinase domain gatekeeper mutation Thr315Ile (T315I) mutation.
7. Bone marrow with ≥ 5% lymphoblasts by morphologic assessment at screening；
8. Eastern cooperative oncology group (ECOG) performance status of 0 to 2.

9. Adequate organ function defined as:

   • Aspartate aminotransferase (AST) ≤3 upper limit of normal (ULN);
   • Serum alanine aminotransferase (ALT) ≤3 ULN;
   • Total bilirubin ≤ 2 ULN, except in individuals with Gilbert's syndrome;
   • Note: Patients with Gilbert's syndrome that bilirubin ≤ 3 ULN and direct bilirubin ≤ 1.5 ULN will be eligible.
   • A serum creatinine≤ 1.5 ULN or Creatine removal rate ≥ 60mL/min（Cockcroft and Gault）
   • Must have a minimum level of pulmonary reserve as ≤ Grade 1 dyspnea and oxygen saturation > 91% on room air.
   • Absolute lymphocyte count ≥0.3 x 10⁹/L.
10. Women of child-bearing potential and all male participants must use highly effective methods of contraception for a period of 1 year after the CD19-CD22 CAR-T cells infusion.

Exclusion Criteria:

1. Active central nervous system leukemia
2. Patients with evidence of currently uncontrollable serious active infections (e.g., sepsis, bacteremia, fungemia, viremia, etc.).
3. Patients who are positive for any of HIV antibody, TP antibody, hepatitis B surface antigen (HBsAg) and hepatitis C virus (HCV) antibody.
4. Major surgery within ≤ 4 weeks before enrollment.
5. Prior malignancy, except carcinoma in situ of the skin or cervix treated with curative intent.

6. Impaired cardiac function:

   • Left Ventricular Ejection Fraction (LVEF) ≤45%;
   • III/IV congestive heart failure (NYHA);
   • Severe arrhythmia (except for Atrial fibrillation, Paroxysmal supraventricular tachycardia);
   • Corrected QT interval (QTc) ≥450ms (male) or QTc≥470ms (female)（QTc using Bazett's formula (QTcB)=QT/RR^0.5）;
   • Myocardial infarction or Coronary Artery Bypass Graft Surgery, heart stent surgery.
   • Other heart diseases that have been judged by the investigator to be unsuitable for receiving cell therapy.
7. Patients with a history of epilepsy or other active central nervous system diseases.
8. Life expectancy < 12 weeks.
9. Allergy to macromolecule biopharmaceuticals such as antibodies or cytokines.
10. Subjects who are receiving systemic steroid treatment and who have been determined by the researchers to require long-term treatment with systemic steroids during treatment, and subjects treated with systemic steroids must be excluded < 72 hours prior to CNCT19 infusion (except inhalation or local use).
11. Patients with other conditions making the patients unsuitable for receiving cell therapy as judged by the investigator.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: A; Single dose of CD19-CD22 CAR-T cells	Biological: CD19-CD22 CAR-T cells; 0.5 to 3.0 x 106 autologous CD19-CD22 CAR-T cells per kg body weight, with a maximum dose of 4 x 108 autologous CD19-CD22 CAR-T cells via intravenous infusion.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Number of participants with treatment-related adverse events as assessed by CTCAE v5.0	24 months
Overall remission rate (ORR)	3 months

Secondary Outcome Measures

Outcome Measure	Time Frame
Duration of remission (DOR)	24 months
Overall survival (OS)	24 months
Response at Day 28 days	1 month
Percentage of patients who achieve complete remission (CR) or complete remission with incomplete blood count recovery (CRi) at month 6 without SCT between CD19-CD22 CAR-T cells infusion and Month 6 response assessment.	6 months
Percentage of patients who achieve CR or CRi with minimal residual disease (MRD) negative bone marrow	6 months
Relapse-free survival (RFS)	24 months

Collaborators and Investigators

• Sponsor: Institute of Hematology & Blood Diseases Hospital, China
• Collaborators: Juventas Cell Therapy Ltd.

Study record dates

Study Major Dates

• Study Start (Actual): September 30, 2019
• Primary Completion (Actual): July 21, 2020
• Study Completion (Actual): December 1, 2020

Study Registration Dates

• First Submitted: July 24, 2019
• First Submitted That Met QC Criteria: July 25, 2019
• First Posted (Actual): July 26, 2019

Study Record Updates

• Last Update Posted (Actual): June 3, 2025
• Last Update Submitted That Met QC Criteria: May 28, 2025
• Last Verified: May 1, 2020

More Information

Terms related to this study

• Keywords: Relapsed; Refractory; B-ALL
• Additional Relevant MeSH Terms: Neoplasms; Immune System Diseases; Neoplasms by Histologic Type; Hematologic Diseases; Lymphatic Diseases; Lymphoproliferative Disorders; Immunoproliferative Disorders; Leukemia; Leukemia, Lymphoid; Precursor Cell Lymphoblastic Leukemia-Lymphoma
• Other Study ID Numbers: QT2019005

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No